Product Code: TMRGL259
The report provides revenue of the global insulin market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global insulin market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the insulin market.
The report delves into the competitive landscape of the global insulin market. Key players operating in the global insulin market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global insulin market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Insulin Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Insulin Market Analysis and Forecast, 2017-2031
5. Key Insights
- 5.1. Regulatory Scenario, by Region/globally
- 5.2. Key Mergers & Acquisitions
- 5.3. Technological Advancements
- 5.4. COVID-19 Pandemics Impact on Industry
6. Global Insulin Market Analysis and Forecast, by Mode of Action
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Mode of Action, 2017-2031
- 6.3.1. Rapid-acting
- 6.3.2. Short-acting
- 6.3.3. Intermediate-acting
- 6.3.4. Premixed
- 6.3.5. Long-acting
- 6.4. Market Attractiveness Analysis, by Mode of Action
7. Global Insulin market Analysis and Forecast, by Source
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Source, 2017-2031
- 7.3.1. Modern Insulin
- 7.3.2. Human Insulin
- 7.4. Market Attractiveness Analysis, by Source
8. Global Insulin market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Market Value Forecast, by Region
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Market Attractiveness Analysis, by Region
9. North America Insulin Market Analysis and Forecast
- 9.1. Introduction
- 9.2. Market Value Forecast, by Mode of Action, 2017-2031
- 9.2.1. Rapid-acting
- 9.2.2. Short-acting
- 9.2.3. Intermediate-acting
- 9.2.4. Premixed
- 9.2.5. Long-acting
- 9.3. Market Value Forecast, by Source, 2017-2031
- 9.3.1. Modern Insulin
- 9.3.2. Human Insulin
- 9.4. Market Value Forecast, by Country, 2017-2031
- 9.4.1. U.S.
- 9.4.2. Canada
- 9.5. Market Attractiveness Analysis
- 9.5.1. By Mode of Action
- 9.5.2. By Source
- 9.5.3. By Country
10. Europe Insulin Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Market Value Forecast, by Mode of Action, 2017-2031
- 10.2.1. Rapid-acting
- 10.2.2. Short-acting
- 10.2.3. Intermediate-acting
- 10.2.4. Premixed
- 10.2.5. Long-acting
- 10.3. Market Value Forecast, by Source, 2017-2031
- 10.3.1. Modern Insulin
- 10.3.2. Human Insulin
- 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Italy
- 10.4.5. Spain
- 10.4.6. Rest of Europe
- 10.5. Market Attractiveness Analysis
- 10.5.1. By Mode of Action
- 10.5.2. By Source
- 10.5.3. By Country/Sub-region
11. Asia Pacific Insulin Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Mode of Action, 2017-2031
- 11.2.1. Rapid-acting
- 11.2.2. Short-acting
- 11.2.3. Intermediate-acting
- 11.2.4. Premixed
- 11.2.5. Long-acting
- 11.3. Market Value Forecast, by Source, 2017-2031
- 11.3.1. Modern Insulin
- 11.3.2. Human Insulin
- 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.4.1. China
- 11.4.2. Japan
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of Asia Pacific
- 11.5. Market Attractiveness Analysis
- 11.5.1. By Mode of Action
- 11.5.2. By Source
- 11.5.3. By Country/Sub-region
12. Latin America Insulin Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Mode of Action, 2017-2031
- 12.2.1. Rapid-acting
- 12.2.2. Short-acting
- 12.2.3. Intermediate-acting
- 12.2.4. Premixed
- 12.2.5. Long-acting
- 12.3. Market Value Forecast, by Source, 2017-2031
- 12.3.1. Modern Insulin
- 12.3.2. Human Insulin
- 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of Latin America
- 12.5. Market Attractiveness Analysis
- 12.5.1. By Mode of Action
- 12.5.2. By Source
- 12.5.3. By Country/Sub-region
13. Middle East & Africa Insulin Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Mode of Action, 2017-2031
- 13.2.1. Rapid-acting
- 13.2.2. Short-acting
- 13.2.3. Intermediate-acting
- 13.2.4. Premixed
- 13.2.5. Long-acting
- 13.3. Market Value Forecast, by Source, 2017-2031
- 13.3.1. Modern Insulin
- 13.3.2. Human Insulin
- 13.3.3. Infection Treatment
- 13.3.4. Gas Embolism
- 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of Middle East & Africa
- 13.5. Market Attractiveness Analysis
- 13.5.1. By Mode of Action
- 13.5.2. By Source
- 13.5.3. By Country
14. Competition Landscape
- 14.1. Market Player - Competition Matrix (by tier and size of companies)
- 14.2. Market Share Analysis, by Company, 2021
- 14.3. Company Profiles
- 14.3.1. Shanghai Fosun Pharmaceutical Co., Ltd.
- 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.1.2. Financial Analysis
- 14.3.1.3. Growth Strategies
- 14.3.1.4. SWOT Analysis
- 14.3.2. Tonghua Dongbao
- 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.2.2. Financial Analysis
- 14.3.2.3. Growth Strategies
- 14.3.2.4. SWOT Analysis
- 14.3.3. Eli Lilly and Company
- 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.3.2. Financial Analysis
- 14.3.3.3. Growth Strategies
- 14.3.3.4. SWOT Analysis
- 14.3.4. Sanofi
- 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.4.2. Financial Analysis
- 14.3.4.3. Growth Strategies
- 14.3.4.4. SWOT Analysis
- 14.3.5. Novo Nordisk A/S
- 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.5.2. Financial Analysis
- 14.3.5.3. Growth Strategies
- 14.3.5.4. SWOT Analysis
- 14.3.6. Julphar
- 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.6.2. Financial Analysis
- 14.3.6.3. Growth Strategies
- 14.3.6.4. SWOT Analysis
- 14.3.7. Biocon Ltd.
- 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.7.2. Financial Analysis
- 14.3.7.3. Growth Strategies
- 14.3.7.4. SWOT Analysis
- 14.3.8. Becton, Dickinson and Company
- 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.8.2. Financial Analysis
- 14.3.8.3. Growth Strategies
- 14.3.8.4. SWOT Analysis
- 14.3.9. Ypsomed AG
- 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.9.2. Financial Analysis
- 14.3.9.3. Growth Strategies
- 14.3.9.4. SWOT Analysis
- 14.3.10. Biodel Inc.
- 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.10.2. Financial Analysis
- 14.3.10.3. Growth Strategies
- 14.3.10.4. SWOT Analysis
- 14.3.11. B. Braun Melsungen AG
- 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.11.2. Financial Analysis
- 14.3.11.3. Growth Strategies
- 14.3.11.4. SWOT Analysis